Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 76-83

  Mitchell, Malcolm S ^a,d,f   Kan Mitchell, June ^a,e   Morrow, Philip R ^a,b   Darrah, Denise ^a   Jones, Vicky E ^a   Mescher, Matthew F ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LIDAK Pharmaceuticals   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f St John Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HLA A2 ANTIGEN; MARIMASTAT; SILICON DIOXIDE; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER REGRESSION; CANCER SIZE; CELL LYSATE; CELL MEMBRANE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LUNG METASTASIS; MALE; MELANOMA; MELANOMA CELL; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; STEM CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HLA-A2 ANTIGEN; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MELANOMA; MIDDLE AGED; REMISSION INDUCTION; SILICON DIOXIDE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1642576146     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0689-3     Document Type: Article

References (28)

1. Mescher, M. F. Surface contact requirements for activation of cytotoxic T lymphocytes. J. Immunol., 149: 2402-2405, 1992.
2. Rogers, J., and Mescher, M. F. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen. J. Immunol., 149: 276-276, 1992.
3. Mescher, M. F., and Savelieva, E. Stimulation of tumor-specific immunity using tumor cell plasma membrane antigen. Methods, 12: 164, 1997.
4. Mescher, M. F., and Rogers, J. D. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide. J. Immunother. Emphasis. Tumor Immunol., 19: 102-112, 1996.
5. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., and Elashoff, R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine (Published erratum appears in Ann. Surg. 217: 309, 1993). Ann. Surg., 216: 463-482, 1992.
6. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., and Elashoff, R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine (Published erratum appears in Ann. Surg. 217: 309, 1993). Ann. Surg., 216: 463-482, 1992.
7. Berd, D., Maguire, H. J., McCue, P., and Mastrangelo, M. J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol., 8: 1858-1867, 1990.
8. Mitchell, M. S., Kan-Mitchell, J., Kempf, R. A., Harel, W., Shau, H., and Lind, S. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant. Cancer Res., 48: 5883-5893 1988.
9. Mitchell, M. S., Harel, W., Kempf, R. A., Kan-Mitchell, J., Boswell, W. D., Hu, E., Dean, G., and Stevenson, L. Active-specific immunotherapy for melanoma. J. Clin. Oncol., 8: 856-869, 1990.
10. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC), 254: 1643-1647, 1991.
11. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
12. Kang, X., Kawakami, Y., el Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. F. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155: 1343-1348, 1995.
13. Mitchell, M. S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol., 25: 623-635, 1998.
14. Mitchell, M. S., Darrah, D., and Stevenson, L. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Cancer Investig., 20: 759-768, 2002.
15. Mitchell, M. S., Harel, W., and Groshen, S. Association of HLA phenotype with clinical response to active specific immunotherapy of melanoma. J. Clin. Oncol., 10: 1158-1168, 1992.
16. Sosman, J. A., Unger, J. M., Liu, P. Y., Flaherty, L. E., Park, M. S., Kempf, R. A., Thompson, J. A., Terasaki, P. I., and Sondak, V. K. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol., 20: 2067-2075, 2002.
17. Curtsinger, J., Deeths, M. J., Pease, P., and Mescher, M. F. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J. Immunol. Methods, 209: 47-57, 1997.
18. Goldberg, J., Shrikant, P., and Mescher, M. F. In vivo augmentation of tumor-specific CTLresponses by class I/peptide antigen complexes on microspheres (Large Multivalent Immunogen). J. Immunol, 170: 228-235, 2003.
19. Fazekas de St. Groth, S. The evaluation of limiting dilutions assays. J. Immunol. Methods, 49: R11-R23, 1982.
20. Bystryn, J. C. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann. N. Y. Acad. Sci., 690: 190-203, 1993.
21. Mitchell, M. S., Harel, W., Kan-Mitchell, J., LeMay, L. G., Goedegebuure, P., Huang, X. Q., Hofman, F., and Groshen, S. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results and possible mechanisms of action. In: J. C. Bystryn, S. Ferrone, and P. Livingston (eds.), Specific Immunotherapy of Cancer with Vaccines. Ann. N. Y. Acad. Sci, vol. 690, pp. 153-166. 1993.
22. Kahn, M., Sugawara, H., McGowan, P., Okuno, K., Nagoya, S., Hellstrom, K. E., Hellstrom, I., and Greenberg, P. CD4 T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing p97 antigen. J. Immunol., 146: 3235-3241, 1991.
23. LeMay, L. G., Kan-Mitchell, J., Goedegebuure, P., Harel, W., and Mitchell, M. S. Detection of human melanoma-reactive CD4+ HLA class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-γ. Cancer Immunol. Immunother., 37: 187-194, 1993.
24. Domenech, N., Henderson, R. A., and Finn, O. J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol., 155: 4766-4774, 1995.
25. Agrawal, B., Krantz, M. J., Reddish, M. A., and Longenecker, B. M. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int. Immunol., 10: 1907-1916, 1998.
26. Reddish, M. A., MacLean, G. D., Koganty, R. R., Kan-Mitchell, J., Jones, V., Mitchell, M. S., and Longenecker, B. M. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer, 76: 817-823, 1998.
27. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
28. Mitchell, M. S., Kan-Mitchell, J., Minev, B., Edman, C., and Deans, R. J. A novel melanoma gene (MG50) encoding the interleukin I receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. Cancer Res., 60: 6448-6456, 2000.